ArticleNature genetics2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Article in Nature genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 746 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Chronic Infection naïve to Antiviral Treatment.
An Unicenter, Prospective, Randomized, Pilot Study Comparing the Effect of Everolimus-containing Versus mTOR Inhibitor Free Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation.
Who cites it
746 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,814 citations in OpenAlex.
- Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies.Scientific reports · 2023Pooled it
- Pooled it
- Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis.Archives of virology · 2021Pooled it
- A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.Medicine · 2016Pooled it
- Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.The pharmacogenomics journal · 2016Pooled it
- Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.Blood · 2021Trial
- Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients.International journal of clinical pharmacy · 2020Trial
- Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs.Journal of medical virology · 2018Trial
- Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.Hepatology (Baltimore, Md.) · 2018Trial
- No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.PloS one · 2018Trial
- Type 1 interferon perturbates clonal competition by reshaping human blood development.Nature genetics · 2026Article
- Role ofResearch square · 2026Article
- Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.Pharmacological reviews · 2026Review
- Lineage-specific chromatin poising enforced by ETS-IRF composite elements determines the divergent interferon responses of plasmacytoid dendritic cells and epithelial cells.bioRxiv : the preprint server for biology · 2026Article
- HCV-Induced Hepatocarcinogenesis: Molecular Mechanisms, Persistent Cancer Risk, and Future Perspectives.Biomedicines · 2026Review
- Interferon-λ3 rs12979860 polymorphism and early-life RSV-bronchiolitis are associated with persistent asthma in male children: a 4-year prospective follow-up study.Pediatric research · 2026Article
- Seasonal variation in respiratory syncytial virus-specific IgG concentrations in Northern Plains American Indian children with asthma.The journal of allergy and clinical immunology. Global · 2025Article
- Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response.Clinical and experimental medicine · 2025Review
- Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trial.Rheumatology and immunology research · 2025Article
- Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review.International journal of molecular sciences · 2025Review
686 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 7 institutions in 4 countries.
Funding
Abstract
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-alpha (PEG-IFN-alpha) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-alpha/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFNlambda3; rs8099917 combined P = 9.25 x 10(-9), OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-alpha.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.